Advertisement

 

 

Ondansetron treatment reduces rotavirus symptoms-A randomized double-blinded placebo-controlled trial.

Ondansetron treatment reduces rotavirus symptoms-A randomized double-blinded placebo-controlled trial.
Author Information (click to view)

Hagbom M, Novak D, Ekström M, Khalid Y, Andersson M, Lindh M, Nordgren J, Svensson L,


Hagbom M, Novak D, Ekström M, Khalid Y, Andersson M, Lindh M, Nordgren J, Svensson L, (click to view)

Hagbom M, Novak D, Ekström M, Khalid Y, Andersson M, Lindh M, Nordgren J, Svensson L,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2017 10 2712(10) e0186824 doi 10.1371/journal.pone.0186824
Abstract
BACKGROUND
Rotavirus and norovirus cause acute gastroenteritis with severe diarrhoea and vomiting, symptoms that may lead to severe dehydration and death. The objective of this randomized double-blinded placebo-controlled study was to investigate whether ondansetron, a serotonin receptor antagonist could attenuate rotavirus- and norovirus-induced vomiting and diarrhoea, which would facilitate oral rehydration and possibly accelerate recovery and reduce need for hospitalization.

METHODS
Children with acute gastroenteritis, aged 6 months to 16 years where enrolled (n = 104) and randomized to one single oral dose (0.15mg/kg) of ondansetron (n = 52) or placebo (n = 52). The number of diarrhoea and vomiting episodes during the 24 hours following treatment was reported as well as the number of days with symptoms. Pathogens in faeces were diagnosed by real-time PCR. Outcome parameters were analyzed for rotavirus- and norovirus-positive children.

RESULTS
One dose of oral ondansetron reduced duration of rotavirus clinical symptoms (p = 0.014), with a median of two days. Furthermore, ondansetron reduced diarrhea episodes, most pronounced in children that had been sick for more than 3 days before treatment (p = 0.028).

CONCLUSION
Ondansetron may be a beneficial treatment for children with rotavirus gastroenteritis.

TRIAL REGISTRATION
European Clinical Trial Database EudraCT 2011-005700-15.

Submit a Comment

Your email address will not be published. Required fields are marked *

five + 13 =

[ HIDE/SHOW ]